AAAAAA

   
Results: 1-12 |
Results: 12
Receptor tyrosine kinases in angiogenesis
Authors: Shawver, LK Lipson, KE Fong, TAT McMahon, G Strawn, LM
Citation: Lk. Shawver et al., Receptor tyrosine kinases in angiogenesis, NEW ANGIOTHERAPY, 2002, pp. 409-452
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts
Authors: Strawn, LM Kabbinavar, F Schwartz, DP Mann, E Shawver, LK Slamon, DJ Cherrington, JM
Citation: Lm. Strawn et al., Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts, CLIN CANC R, 6(7), 2000, pp. 2931-2940
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
Authors: Mendel, DB Schreck, RE West, DC Li, GM Strawn, LM Tanciongco, SS Vasile, S Shawver, LK Cherrington, JM
Citation: Db. Mendel et al., The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function, CLIN CANC R, 6(12), 2000, pp. 4848-4858
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
Authors: Mendel, DB Laird, AD Smolich, BD Blake, RA Liang, CX Hannah, AL Shaheen, RM Ellis, LM Weitman, S Shawver, LK Cherrington, JM
Citation: Db. Mendel et al., Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent, ANTI-CAN DR, 15(1), 2000, pp. 29-41
Biotransformation of the anti-angiogenic compound SU5416
Authors: Antonian, L Zhang, HB Yang, C Wagner, G Shawver, LK Shet, M Ogilvie, B Madan, A Parkinson, A
Citation: L. Antonian et al., Biotransformation of the anti-angiogenic compound SU5416, DRUG META D, 28(12), 2000, pp. 1505-1512
New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
Authors: Cherrington, JM Strawn, LM Shawver, LK
Citation: Jm. Cherrington et al., New paradigms for the treatment of cancer: The role of anti-angiogenesis agents, ADV CANC R, 79, 2000, pp. 1-38
Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu plus MMTV/TGF-alpha bigenic mice
Authors: Lenferink, AEG Simpson, JF Shawver, LK Coffey, RJ Forbes, JT Arteaga, CL
Citation: Aeg. Lenferink et al., Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu plus MMTV/TGF-alpha bigenic mice, P NAS US, 97(17), 2000, pp. 9609-9614
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity
Authors: Busse, D Doughty, RS Ramsey, TT Russell, WE Price, JO Flanagan, WM Shawver, LK Arteaga, CL
Citation: D. Busse et al., Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity, J BIOL CHEM, 275(10), 2000, pp. 6987-6995
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
Authors: Laird, AD Vajkoczy, P Shawver, LK Thurnher, A Liang, C Mohammadi, M Schlessinger, J Ullrich, A Hubbard, SR Blake, RA Fong, TAT Strawn, LM Sun, L Tang, C Hawtin, R Tang, F Shenoy, N Hirth, KP McMahon, G Cherrington, JM
Citation: Ad. Laird et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, CANCER RES, 60(15), 2000, pp. 4152-4160
Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models
Authors: Rosenblum, MG Shawver, LK Marks, JW Brink, J Cheung, L Langton-Webster, B
Citation: Mg. Rosenblum et al., Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models, CLIN CANC R, 5(4), 1999, pp. 865-874
Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGFreceptor tyrosine kinases
Authors: Sun, L Tran, N Liang, CX Tang, F Rice, A Schreck, R Waltz, K Shawver, LK McMahon, G Tang, C
Citation: L. Sun et al., Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGFreceptor tyrosine kinases, J MED CHEM, 42(25), 1999, pp. 5120-5130
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
Authors: Fong, TAT Shawver, LK Sun, L Tang, C App, H Powell, TJ Kim, YH Schreck, R Wang, XY Risau, W Ullrich, A Hirth, KP McMahon, G
Citation: Tat. Fong et al., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, CANCER RES, 59(1), 1999, pp. 99-106
Risultati: 1-12 |